Abstract Interferon‐α (IFN‐α) alone or in combination with cytostatic drugs can induce major
and durable cytogenetic responses in about 20 to 25% of chronic myeloid leukemia (CML) …

Interferon-alpha produces a complete hematologic and cytogenetic remission in
approximately 20% of patients with chronic myelogenous leukemia (CML). In this study, we …

Using a highly sensitive fluorescence in situ hybridization method with probes for BCR and
ABL1 (D-FISH), we studied 37 paired sets of bone marrow and blood specimens, collected …

Background: Several attempts have been made to determine whether interphase
fluorescence in situ hybridization (I-FISH) on bone marrow or peripheral blood specimens is …

There is a need for fast and sensitive methods to evaluate the response of patients with
chronic myeloid leukaemia (CML) to interferon‐α (IFN‐α) therapy to complement cytogenetic …

In order to analyze the efficiency of interphase FISH for the detection and monitoring of Ph+
cells in chronic myelogenous leukemia (CML) under interferon (IFN) treatment, the following …

We used two-color fluorescence in situ hybridization (FISH) to detect BCR/ABL fusion in
interphase nuclei in bone marrow of 17 patients with chronic myeloid leukemia (CML) before …

Cytogenetic analysis is considered pivotal for assessing the remission rate in CML patients
on IFN therapy. On the basis of general agreement, at least 25 metaphases should be …

Interferon-alpha (IFN-alpha) has become a widely used treatment modality in chronic
myelogenous leukemia (CML) and was shown to induce complete hematologic responses …

Aims: Recombinant alpha‐interferon (r‐IFN) is an effective therapy for chronic myeloid
leukaemia (CML), inducing haematological and major cytogenetic response in 70% and …